{
  "name" : "dacemirror.sci-hub.se_journal-article_0ac81f008f3e8a1624c096342fceec1e_min2019.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Biomimetic Metal–Organic Framework Nanoparticles for Cooperatively Combination of Antiangiogenesis and Photodynamic Therapy for Enhanced Efficacy",
    "authors" : [ "Huan Min", "Jing Wang", "Yingqiu Qi", "Yinlong Zhang", "Xuexiang Han", "Ying Xu", "Junchao Xu", "Yao Li", "Long Chen", "Keman Cheng", "Guangna Liu", "Na Yang", "Yiye Li", "Guangjun Nie" ],
    "emails" : [ "zhangyl@nanoctr.cn;", "liyy@nanoctr.cn;", "niegj@nanoctr.cn" ],
    "sections" : [ {
      "heading" : null,
      "text" : "CommuniCation\n1808200 (1 of 11) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.advmat.de"
    }, {
      "heading" : "Biomimetic Metal–Organic Framework Nanoparticles",
      "text" : "for Cooperatively Combination of Antiangiogenesis and Photodynamic Therapy for Enhanced Efficacy"
    }, {
      "heading" : "Huan Min, Jing Wang, Yingqiu Qi, Yinlong Zhang,* Xuexiang Han, Ying Xu,",
      "text" : "Junchao Xu, Yao Li, Long Chen, Keman Cheng, Guangna Liu, Na Yang, Yiye Li,* and Guangjun Nie*\nDr. H. Min, Prof. J. Wang, Dr. Y. Qi, Dr. Y. Zhang, Dr. X. Han, Dr. Y. Xu, Dr. J. Xu, Dr. Y. Li, Dr. L. Chen, Dr. K. Cheng, Dr. G. Liu, Dr. N. Yang, Prof. Y. Li, Prof. G. Nie CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology Beijing 100190, China E-mail: zhangyl@nanoctr.cn; liyy@nanoctr.cn; niegj@nanoctr.cn Prof. J. Wang, Dr. Y. Zhang, Dr. X. Han, Dr. Y. Xu, Dr. J. Xu, Dr. L. Chen, Dr. N. Yang, Prof. Y. Li, Prof. G. Nie Center of Materials Science and Optoelectronics Engineering University of Chinese Academy of Sciences Beijing 100049, China Dr. Y. Qi School of Basic Medical Sciences Zhengzhou University Zhengzhou, Henan 450001, P. R. China\nThe ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adma.201808200.\nDOI: 10.1002/adma.201808200\nPhotodynamic therapy (PDT) is an emerging anticancer therapeutic approach that utilizes photosensitizers under light irradiation to generate reactive oxygen species (ROS) cytotoxic against solid tumors.[1,2] Already approved for clinical treatment of various types of malignancies, PDT presents several very attractive advantages, especially its minimally invasive and selective manner enabled by localized irradiation, leading to considerably lower side effects compared with conventional treatments.[3–6] Apart from directly killing tumor cells, PDT also elicits other therapeutic responses in the targeted tissue including vascular damage and immune response activation, and the effective combination of multiple mechanisms has been thought to be important for long-term inhibition of PDT-treated tumor.[7,8] Nonetheless, the massive cell death and vasculature shutdown initially induced by PDT was usually followed by a consequent elevation in the production of many protumor factors, particularly angiogenic factors such as vascular endothelial growth factor (VEGF), by\nthe surviving tumor cells, facilitating tumor regrowth or relapse as well as metastasis.[9,10] This has led to a series of attempts that apply antiangiogenesis agents to neutralize the angiogenic response of tumor during or after PDT.[11,12] For example, Hasan and colleagues demonstrated that administration of VEGF inhibitor TNP-470 after PDT treatment improved the control of tumor in mice.[13] A similar study also reported that anti-VEGF monoclonal antibody was able to significantly improve tumor responsiveness of PDT.[14] So far, most of the existing combination strategies were realized via sequential systemic administration of a conventional photosensitizer and an antiangiogenic drug, which often causes side effects due to nonspecific tissue distribution and high doses of these agents.[15,16] In the recent years, it has been suggested that nanoparticle-based targeted delivery may be an promising approach to enhance tumor-specific accumulation of photosensitizer or other agents, reducing their required dose as well as toxicity. Being capable to simultaneously deliver multiple drugs, the use of nanocarriers also greatly facilitates combined treatments.[17,18] However, even though loading\nPhotodynamic therapy (PDT) is a promising anticancer treatment and is clinically approved for different types of tumors. However, current PDT suffers several obstacles, including its neutralization by excess glutathione (GSH) in the tumor tissue and its strongly proangiogenic tumor response. In this work, a biomimic, multifunctional nanoparticlebased PDT agent, combining a tumor-targeted photosensitizer with GSH scavenging and antiangiogenesis therapy, is developed. A porphyrinic Zr–metal–organic framework nanoparticle is used simultaneously as the photosensitizer and the delivery vehicle of vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor apatinib. The core nanoparticles are wrapped in MnO2 to consume the intratumoral GSH and then decorated with a tumor cell membrane camouflage. After intravenous administration, the nanoparticles selectively accumulate in tumor through homotypic targeting mediated by the biomimic decoration, and the combination of enhanced PDT and antiangiogenic drug significantly improves their tumor inhibition efficiency. This study provides an integrated solution for mechanism-based enhancement of PDT and demonstrates the encouraging potential for multifunctional nanosystem applicable for tumor therapy."
    }, {
      "heading" : "Cancer Therapy",
      "text" : "Adv. Mater. 2019, 1808200\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808200 (2 of 11)\nphotosensitizer into nanoparticles has resulted in significantly higher efficacy in many previous reports, this improvement is still limited by several challenges, either related to the complicated in vivo fate of the nanosystem (off-target accumulation, early clearance, untimely cargo release) or to other available mechanisms for the tumor to resist PDT itself.[19–21] For instance, apart from the angiogenic post-treatment response, tumor cells also produce excessive levels of glutathione (GSH), which is able to consume ROS generated during the PDT treatment and compromise its tumor cell killing efficacy.[22]\nTo develop an integrated, multileveled solution to this set of problems, we have engineered a biomimetic metal-organic framework (MOF) nanoplatform for combined PDT and antiangiogenic therapy. As a new generation of hybrid porous materials, MOF nanostructures enable highly versatile combination of inorganic building blocks and organic linkers, favoring their increasing utility in biological application.[23] Through molecular design of the organic components, photosensitive moieties (mostly porphyrinic) could readily be engineered into the MOF structure, resulting in stable porous nanostructures with excellent PDT activity and tunable size or surface chemistry.[24] Compared to freely administered or nanoparticle encapsulated photosensitizers, such MOF-based photosensitizers effectively reduced self-quenching and have been reported to show high photosensitizer loading efficiency as well as enhanced therapeutic outcome.[25] In the case of combination therapy, their porous inner structure also provide excellent loading sites and protection for small molecular drugs.[26] Currently, the major obstacles for medical application of MOFs remain to be their short blood half-life and unfavorable biocompatibility,[27,28] and strategies to optimize the in vivo properties of this type of nanomaterial are already attracting much interest.\nDrawing inspiration from circulating blood cells, biomimetic cloaking with plasma membrane has recently emerged as a powerful technique to tune the in vivo fate of inorganic nanomaterials.[29,30] Many types of cell membranes have been utilized to camouflage nanoparticles allowing them to escape macrophage recognition in the bloodstream and reducing their toxicity.[31,32] Such design became especially attractive when the surface proteins inherited from the donor cell were able to endow the biomimetic particles additional biological functionality.[30,33] Aiming to improve both the biodistribution and pharmacokinetics of photosensitive MOFs, we have opted to decorate porphyrinic MOF-based nanoparticles, acting both as agent for PDT and delivery vehicle for antiangiogenesis therapy, with breast cancer cell membrane to enhance their performance in a mouse breast tumor model. Since tumor cells display particularly strong cell–cell communication and tend to escape\nimmune attack in the blood, their extracted membrane as biomimetic coating was not only reported to prolong the blood half-life of synthetic nanoparticles but could also mediate the particles to selectively target source tumor cells in vivo.[34,35]\nOur work demonstrated the construction of a photosensitive porphyrinic Zr-MOF (PCN-224) nanostructure, loaded with vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor apatinib and coated in a layer of MnO2, whose exterior surface was further decorated with cell membrane extracted from mouse breast cancer cell line 4T1. Apatinib is an antiangiogenic agent approved by Food and Drug Administration (FDA) for first-line treatment of gastric cancer.[36] The MnO2 shell served as a reducing agent scavenger to neutralize the elevated production of GSH in the tumor tissue mentioned above, with additional benefit in that the reaction product Mn2+ could be used as a magnetic resonance imaging (MRI) contrast agent for in vivo tumor imaging.[37] In a 4T1 tumor model, this integrated nanosystem (designated as aMMTm; Scheme 1a) was expected to enjoy a tumor targeting advantage due to the homotypic affinity conferred by its 4T1 membrane camouflage, while\nAdv. Mater. 2019, 1808200\nScheme 1. Schematic illustration of aMMTm preparation and proposed combination therapy of PDT and antiangiogenesis. a) The construction of porphyrinic metal–organic framework nanoparticle aMMTm through drug loading, MnO2 coating and tumor cell membrane decoration. b) Proposed action mechanism of aMMTm in a mouse tumor model. The tumor cell membrane camouflage may help the nanoparticles to escape early clearance and to target tumor tissue through homotypic affinity. At the tumor site, the MnO2 shell reacted with GSH either in the microenvironment or in the tumor cells to consume the excessive GSH and boost the effect of PDT. The meanwhile generated Mn2+ could be used as an MRI contrast agent. When the MnO2 shell was degraded, released apatinib neutralized the PDT-induced revascularization, and prevented tumor progress.\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808200 (3 of 11)\nat the tumor site its inner MnO2 shell would act to deplete the excessive GSH, sensitizing the tumor tissues for the subsequent PDT. Moreover, the decomposition of MnO2 by GSH also triggers the release of encapsulated apatinib to block the PDT-induced angiogenic process. This nanoparticle-based PDT approach unites mechanism-based enhancement of PDT and problem-oriented engineering of the nanoplatform and may serve to facilitate both the ablation and the control of PDTtreated tumors without overt side effects (Scheme 1b).\nMOF (PCN-224) core nanoparticles were synthesized using a solvothermal method according to previous report.[24] The prepared MOF was mixed with apatinib in N,N-dimethylformamide (DMF) and stirred for 12 h to obtain apatinib-loaded MOF (aM). Subsequently, a MnO2 coating layer was deposited onto the\nnanoparticle surface through reduction of KMnO4 with the aid of poly(allylamine hydrochloride) (PAH), to produce MnO2 coated MOF (MOF@MnO2) or aM (aMM). Purified 4T1 tumor cell membrane was then mixed with different MOF-containing nanoparticles and sonicated for 30 min to form the biomimetic decoration.\nThe prepared nanoparticles were first characterized using transmission electron microscopy (TEM) and dynamic light scattering (DLS). Bare MOF nanoparticles without any coating or drug loading showed a roughly spherical shape (Figure 1a) and uniform size distribution with an average hydrodynamic diameter of 121.3 nm and positively charged surface (zeta potential 28.1 ± 2.2 eV). After being loaded with apatinib and subsequently coated with MnO2 coating (denoted as aMM), their average diameter increased to 122.2 and 140.5 nm,\nAdv. Mater. 2019, 1808200\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808200 (4 of 11)\nrespectively, with the surface remaining positively charged (zeta potential 29.7 ± 2.8 and 44.5 ± 1.9 eV, respectively). The final nanoparticles cloaked with extracted 4T1 cell membrane (aMMTm) displayed a clear core–shell structure under TEM (Figure 1a) and has an average hydrodynamic diameter of 178.4 nm, while the surface charge was reversed (zeta potential −33.6 ± 2.8 eV; Figure 1b,c). The size and surface charge of these nanomaterials used in the following experiment were summarized in Table S1 in the Supporting Information. Elemental distribution within the aMM nanoparticles according to energy dispersive X-ray spectroscopy (EDS) revealed a heavier deposition of Mn in the peripheral layer compared to the deeper core, while Zr was uniformly distributed within the core region, implying the formation of MnO2 shell (Figure 1d). As for the successful cloaking with cell membrane, SDS–PAGE (sodium dodecyl sulfate−polyacrylamide gel electrophoresis) was performed to compare the membrane protein components extracted from fresh 4T1 cells and the aMMTm final product. Figure 1e confirmed that no obvious protein loss has occurred during the coating process and the integrity of cell membrane has been conserved after decoration. The MOF core demonstrated excellent encapsulation efficiency of apatinib (>98.3%), and when the MOF: apatinib mass ratio was set at 1: 0.5, the final drug loading efficiency reached 32.9% (Table S2, Supporting Information), and this ratio was used for the following experiments. The drug-loaded aMMTm particles were experimentally stable and no significant change was observed in their size and zeta potential after incubation in phosphate buffered saline (PBS) until 6 days at pH 7.4 (Figure S1, Supporting Information).\nTo verify the GSH scavenging activity and GSH-triggered apatinib release from aMMTm, an intracellular GSH assay was detected on 4T1 cells before and after nanoparticle treatment. Incubation with apatinib-loaded MOF core (no MnO2 coating; referred to as aM nanoparticles) did not cause any significant change in the intracellular GSH concentration. In contrast, after being treated with aMM and aMMTm for 5 h, the GSH level in 4T1 cells decreased more than 50% (Figure S2, Supporting Information). No significant difference in GSH depleting ability was observed between these two types of MnO2 coated nanoparticles. When aMM nanoparticles were incubated in 2 × 10−3 m GSH solution, within 10 min the color of solution changed from deep yellow to pale yellow (Figure S3a, Supporting Information), implying the dissolution of MnO2. In fact, EDS analysis also demonstrated that GSH treatment has considerably weakened the overall Mn signal in the particle, and the strong Mn deposition at the outer layer almost disappeared (Figure S3b, Supporting Information). This GSH-dependent decomposition of MnO2 shell was also confirmed by the drug release profile of aMMTm nanoparticle. In the absence of GSH, after 24 h only ≈20% of encapsulated apatinib was released. When 2 × 10−3 m GSH was added to the solution, this rate increased to ≈50%, and when treated with 10 × 10−3 m GSH, more than 98% apatinib was released within 24 h (Figure 1f). These results suggested that the MnO2 shell in aMMTm could effectively deplete GSH in tumor cells and enable GSH-triggered drug release regardless the cell membrane decoration.\nHomotypic affinity between cancer cell membrane camouflaged nanoparticles and the source cancer cells has been considered critical for their tumor targeting. To investigate this selective\naffinity, we prepared a series of apatinib-loaded, MnO2 coated MOF nanoparticles with different outmost decoration and compared their internalization by 4T1 cells to that of aMMTm. 4T1 cells were incubated with nanoparticles cloaked with liposome, cell membrane of human endothelial cell line human umbilical vein endothelial cell (HUVEC), or that of mouse pancreatic cancer cell line Pan02 (referred to as aMML, aMMHm, and aMMPm, respectively), and aMMTm for 6 h. When observed by a confocal microscope, aMMTm showed considerably higher cell binding and/or uptake than nanoparticles with any other decoration (Figure 2a). Quantitative results by flow cytometry further demonstrated the particularly strong association between 4T1 cells and aMMTm (Figure 2b,c). Notably, neither membranes derived from human cell line (aMMHm) nor those from a nonrelated type of mouse cancer cell (aMMPm) showed significantly stronger affinity with 4T1 cells than the artificial phospholipid bilayer coating of aMML. We next investigated whether the camouflage of cancer cell membrane also affected the internalization by macrophages. Contrary to the case of tumor cells, confocal microscopy (Figure 2d) and flow cytometry (Figure 2e,f) both indicated that macrophage cell line Raw264.7 showed significantly reduced (>75% as estimated by flow cytometry) binding and/or internalization of aMMTm compared to that of aMML. This was consistent with previous study suggesting that cell membrane camouflage typically reduced the clearance of nano particles by reticular endothelial system,[38] and implied that 4T1 membrane decoration may serve to improve the short half-life of traditional MOF nanomaterials in vivo.\nIn vitro cytotoxicity of different formulations of MOF nanoparticles were tested both in the absence and presence of light irradiation. Without light, no significant toxicity of aM, aMM or aMMTm was detected until the equivalent MOF dose reached 20 µg mL−1 (Figure 3a) which was also the dose selected for other in vitro experiments. The tumor cell killing efficiency of each nanosystem was estimated under two different irradiances. 4T1 cells were first incubated with the nanoparticles for 5 h before being subjected to 30 min irradiation. Cell viability assay indicated that all three nanoformulations exhibited a significant and intensity-dependent cytotoxicity against 4T1 cells in the presence of light (Figure 3b). Formulations containing the MnO2 shell, aMM and aMMTm, both showed significantly enhanced PDT-induced cytotoxicity compared to the naked MOF, and aMMTm has the highest killing efficiency probably due to increased internalization caused by the homotypic targeting. Apoptosis assay after nanoparticle treatment and irradiation confirmed these trends in toxicity indicating that aMMTm had the strongest capability to induce PDT-related apoptosis in 4T1 cells (Figure 3c,d). Propidium iodide (PI) staining for dead cells also demonstrated similar results (Figure 3e).\nTo assess whether the biomimic camouflage design could function as intended in vivo, we first studied the plasma pharmacokinetics and biodistribution of aMMTm in mice. After intravenously administered with aM, aMML, and aMMTm, BALB/c mice were subjected to sequential blood sampling via tail incision (10 µL each time) at different time intervals and the concentrations of MOF were measured by its fluorescence emission at 660 nm (Figure S4, Supporting Information). The uncoated MOF nanoparticles aM were quickly cleared from the bloodstream, while both aMMTm and aMML\nAdv. Mater. 2019, 1808200\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808200 (5 of 11)\nAdv. Mater. 2019, 1808200\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808200 (6 of 11)\nshowed a prolonged circulation time. The half-lives of the three nanoformulations were respectively 0.4 h for MOF, 3 h for aMML, and 3.5 h for aMMTm according to a one-compartment open model (Figure S5, Supporting Information). The nanoparticles with different membrane decorations were then investigated for their biodistribution and tumor targeting efficiency. To facilitate fluorescence imaging, BALB/c nude mice bearing implanted 4T1 tumors were used and after injection with aMML, aMMHm, aMMPm, or aMMTm, distribution of the MOF fluorescence was imaged both in vivo and ex vivo. From 6 h postinjection, the fluorescence signal within the tumor region became notably stronger in the aMMTm treated mice than in any other groups (Figure 4a), and ex vivo imaging results of excised tumors 24 h after injection confirmed this enhanced accumulation (Figure 4b,c). At 24 h postinjection, only weak fluorescence was observed in liver, lung, and kidney, while almost no signal was detected in heart, spleen and brain (Figure 4b,c). This could reflect the previously reported liver\nAdv. Mater. 2019, 1808200\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808200 (7 of 11)\nclearance and lung retention of nanosized particles,[39] which may be followed by the degradation of MOF core into small particles (<10 nm) or small molecules containing porphyrin moiety and their kidney-dependent clearance. Intratumoral presence of MOF nanoparticles was also visualized in tumor sections by a confocal microscope, and consistent with previous results, the aMMTm treated tumors showed the highest MOFrelated fluorescence intensity (Figure 4d). Furthermore, since the arrival of our nanoparticles at the tumor site was expected to be followed by the GSH-mediated decomposition of MnO2 shell, we have also monitored the yield of Mn2+ within the tumor tissue after nanoparticle administration. The feasibility to use Mn2+ dissolved by GSH from aMMTm as MRI contrast agent was first tested in vitro (Figure S6, Supporting Information). We therefore compared the magnetic resonance (MR) images of aMML and aMMTm treated tumor tissues at diverse time points postinjection to confirm the homotypic tumor targeting mediated by 4T1 membrane. Although an increase of T1\nAdv. Mater. 2019, 1808200\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808200 (8 of 11)\ncontrast in tumor region was also observed in the aMML treated mouse, this enhancement was in fact stronger in the aMMTm treated group (Figure 4f,g), reaching its maximum at 6 h postinjection, which was also the time interval selected for laser irradiance in the PDT experiments. All these indicated that our biomimic decoration could effectively enhance the tumor accumulation of nanoparticles through homotypic targeting effect.\nBased on these results, we have then evaluated the therapeutic efficacy of aMMTm as platform for PDT combined with antiangiogenic treatment. BALB/c mice bearing 4T1 tumors (≈100 mm3) were randomly divided into eight groups. Three types of MOF nanoparticles loaded with apatinib, aMMTm, aMML, and aMTm (coated with 4T1 membrane but not MnO2) as well as two formulations for single PDT, MML, and MMTm (i.e., aMML and aMMTm without the antiangiogenic drug, respectively) were prepared and administered intravenously. The equivalent doses of MOF and apatinib in each injection were set at 10 and 5 mg kg−1 body weight, respectively. The treatments were repeated once every 2 d for three times in total (Figure 5a) with or without light irradiation (660 nm, 100 mW cm−2, 30 min) applied 6 h postinjection. Two weeks after the treatment started, the tumor volume of mice treated by aMMTm-based PDT only slightly increased (normalized tumor growth curves in Figure 5b), demonstrating significantly better therapeutic effect than any other groups. Tumor weights at the end of experiment also indicated the enhanced antitumor efficacy of aMMTm (Figure 5c,d). The other two formulations that allowed combination therapy (aMTm and aMML) also achieved considerable efficacy when applied together with irradiation, superior to any other controls but did not effectively control the growth of tumor. Interestingly, MOF nanoparticles with MnO2 and 4T1 membrane coating but without apatinib (MMTm) showed similar antitumor activity during the early stage of investigation, yet after several days the tumor resumed\nAdv. Mater. 2019, 1808200\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808200 (9 of 11)\nrapid growth. This implied that the combination with apatinib was necessary for the effect of nanoparticle-based PDT to sustain when the treatment stopped. None of the nanoparticles, including the apatinib-loaded ones, showed significant tumor inhibition without light irradiation, possibly indicating that in our model the antiangiogenic drug was much more effective as a supplement for other treatments that killed tumor cells, than as a singly used antitumor agent. No observable changes in body weight had occurred in any of the groups during the investigation (Figure S7, Supporting Information).\nAfter the terminal of therapeutic experiments, the excised tumors were sliced for histological examination. Both necrosis and apoptosis analyses, conducted by hematoxylin and eosin (H&E) staining (Figure 5e) and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining (Figure 5f and Figure S8, Supporting Information), respectively, showed that aMMTm (with light irradiation) had caused the highest degree of damage compared to other nanoformulations. Vessel density and VEGF signaling in the tumor tissue was then examined to confirm the antitumor mechanism of combination therapy. For the tumors singly treated with MOF-based PDT (MMTm + light), a notably higher blood vessel density (visualized by anti-CD31 immunohistochemistry; Figure S9a,b, Supporting Information) and VEGF expression (Figure S10a,b, Supporting Information) compared to the saline group was observed, even if their average final volume was actually smaller. No observable angiogenic change was induced by irradiation only. This could explain the resumed fast growth rate of MMTm-treated tumors shortly after the last PDT treatment.[11,12] However, all the apatinib-containing nanoformulations, aMML, aMTm, and aMMTm, significantly reduced the vessel density and VEGF levels in the PDT-treated tumor tissue, with aMMTm showing the highest efficiency. Taken together, these data suggested that nanoparticle-delivered apatinib significantly neutralized the strong angiogenic tumoral response to PDT, and this mechanism-based combination was likely the principal factor underlying the enhanced antitumor activity of aMMTm. Biomimic membrane-mediated homotypic tumor targeting and enhanced PDT toxicity by GSH depletion also contributed to this enhancement.\nBiocompatibility of the nanoparticles was also assessed after the therapeutic experiment. At the end of investigation, the major organs of nanoparticle-treated mice were subjected to histological examination, which did not signal any overt damage (Figure S11, Supporting Information). Blood samples were also collected before the mice were euthanized, and serum biochemical indicators for heart, liver, and renal function also showed no significant difference between mice treated with saline and those treated with aMMTm (Figure S12, Supporting Information). These implied good biocompatibility of aMMTm nanoparticles in the normal organs.\nIn conclusion, we have developed a multifunctional biomimic MOF nanoparticle with cancer cell membrane camouflage, for anticancer combination therapy of PDT and antiangiogenesis. The porphyrinic MOF nanostructure served simultaneously as PDT agent and drug delivery vehicle, with tumor-targeting capability and optimized in vivo fate endowed by 4T1 membrane decoration. A MnO2 layer deposited on the MOF core was particularly introduced to neutralize excessive\nintratumoral GSH and enhance PDT efficiency. When delivered by this nanoparticle, antiangiogenic drug apatinib showed excellent synergistic effects with MOF-based PDT, inhibiting the protumoral post-PDT angiogenesis, and the nanosystem demonstrated promising tumor targeting and therapeutic efficacy. Offering a precise design to compact solutions for multiple obstacles in PDT into a single formulation, we believe this nanosystem also has potential for further combination with other therapies and demonstrated the great capacity of engineered nanomaterials in mechanism-based customization of anticancer treatments."
    }, {
      "heading" : "Experimental Section",
      "text" : "Materials: Zirconyl chloride octahydrate (ZrOCl2·8H2O), 5,10,15,20- tetrakis (4-carboxyphenyl) porphyrin (H2TCPP), benzonic acid, DMF, and potassium permanganate (KMnO4) were purchased from SigmaAldrich (Shanghai, China). Poly(allylamine hydrochloride) (PAH), lectin, cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) were purchased from Sinopharm (Beijing, China). Apatinib was purchased from Tengzhun Biotechnology Co., Ltd (Shanghai, China). Materials for cell culture, including PBS, Roswell Park Memorial Institute (RPMI)-1640 medium, Dulbecco’s modified Eagle medium (DMEM), Kaighn’s modification of Ham’s F-12 medium (F-12K), and fetal bovine serum (FBS), were purchased from Wisent Corporation (Wisent, Canada). 35 mm confocal petri dishes (Hangzhou Xinyou Biotechnology Co., Ltd) were purchased from Hualide Technologies Co Ltd. Hoechst 33342 (C0030, China) and radio immunoprecipitation assay (RIPA) lysis buffer (R0010, China) were from Solarbio Life Science. Calcein acetoxymethyl ester (Calcein AM), Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) cell apoptosis kit, membrane protein extraction kit, GSH assay kit, and phenylmethanesulfonyl fluoride were purchased from Beyotime Institute of Biotechnology (China). Antimouse CD31 antibody (ab28364) and antimouse vascular endothelial growth factor A (VEGFA) antibody (ab1316) were purchased from Abcam.\nInstruments: A JEM200CX transmission electron microscope (Jeol Ltd., Tokyo, Japan) and a Zetasizer Nano-ZS Particle Sizer and Zeta Potential Analyzer (Malvern Instruments, UK) were used for characterization of nanomaterials. Confocal fluorescence images were obtained by an LSM 710 confocal laser scanning microscope (Carl Zeiss SMT Inc., USA). Flow cytometry analysis was performed by an Accuri C6 flow cytometer (BD Biosciences, USA). A Maestro in vivo fluorescent imaging system (CRi Maestro, USA) was used for in vivo and ex vivo imaging. T1-weighted MRI was performed by a BioSpec70/20USR 7.0 T MRI scanner (Bruker, Germany).\nSynthesis of Zr-Based Porphyrinic MOF: MOF nanoparticles were synthesized according to previous literature.[8] Briefly, ZrOCl2·8H2O (300 mg), H2TCPP (100 mg, and benzoic acid (BA) (2.8 mg) were dissolved in 100 mL of DMF and stirred at 90 °C for 5 h under nitrogen atmosphere protection. After cooling to the room temperature, the MOF product was collected by centrifugation at 10 000 g for 30 min and washed for three times with DMF. The synthesized MOF was stored in DMF at 4 °C and washed for three times with deionized water before experimental usage.\nSynthesis of MOF@MnO2: 5 mg MOF was dispersed in 5 mL deionized water in which was dissolved 10 mg PAH, and the mixture was stirred at 900 rpm for 2 h. Then 100 µL aqueous solution of KMnO4 (10 mg mL−1) was added dropwise and stirred again for 2 h. The purple color of MOF turned to yellowish-brown after the successful coating with MnO2.\nPreparation of Cell Membrane Fragments: Cell membrane fragments were collected using a Membrane Protein Extraction Kit. In brief, 4T1, HUVEC or Pan02 cells were cultured, collected, and dispersed in membrane protein extraction buffer solution, and the cells were\nAdv. Mater. 2019, 1808200\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808200 (10 of 11)\nsubjected to ultrasound probe sonication in ice bath for 3 min. The mixture was then centrifuged (700 g, 10 min, 4 °C), and the supernatant was further centrifuged at 14 000 g for 30 min (4 °C). Finally, the extracted cell membrane fragments were quantified by a bicinchoninic acid (BCA) protein quantitation Kit, and stored at −80 °C for further usage.\nPreparation of Membrane Camouflaged Nanoparticles: For cell membrane coating, the prepared cell membrane fragments were mixed with MOF or MOF@MnO2 nanoparticles at a nanoparticle-to-membrane weight ratio of 5:1. The mixture was sonicated in a bath sonicator for 30 min and the product was centrifuged and collected. Liposomes were also prepared for the phospholipid bilayer coated nanoparticles (MML and aMML). Lecithin (10 mg), cholesterol (5 mg), and DSPE-PEG2000 (1 mg) were dissolved by 10 mL dichloromethane in a round-bottom flask. After rotary evaporation for 40 min, a thin transparent film was formed. Tri-distilled water was then added the film was allowed to hydrate for 20 min at 50 °C. MOF@MnO2 nanoparticles were then mixed with the liposome at weight ratio of 5:1 and sonicated for 30 min.\nLoading and Release of Apatinib: To prepare apatinib-loaded nanoparticles, naked MOF nanoparticles were mixed with apatinib in DMF with different weight ratios and stirred in darkness at room temperature for 12 h. The apatinib@MOF (aM) nanoparticles were collected by centrifugation at 10 000 g for 30 min and washed first with DMF, then with water for two times each to remove the free apatinib. The product could be then coated with MnO2 and decorated with membranes as described above. To determine the drug encapsulation efficiency and loading efficiency, the aM was dissolved by PBS and apatinib was quantified by high-performance liquid chromatography (HPLC). For the GSH-dependent drug release, aMMTm was treated with PBS containing different concentrations of GSH and at different time intervals the released apatinib was determined by HPLC.\nCell Culture: 4T1 cells were cultured in RPMI-1640 medium with 10% FBS and 1% penicillin/streptomycin. HUVEC cells were cultured in F-12K medium (containing 10% FBS, 0.1 g mL−1 heparin, 5% endothelial cell growth supplement, and 1% penicillin/streptomycin). Pan02 cells were cultured in DMEM with 10% FBS and 1% penicillin/streptomycin. All cells were cultured at 37 °C in a humidified 5% CO2 atmosphere.\nCytotoxicity Assay: 4T1 cells were seeded in 96-well plates at a density of 5 × 103 cells per well for 24 h and then treated with different concentrations (0, 0.5, 1, 2, 5, 10, 20, 50, and 100 µg mL−1, as an equivalent dosage of MOF) of aM, aMM, and aMMTm or with PBS. After 24 h incubation, the cell viability was evaluated using a cell counting kit-8 (CCK-8) kit (Dojindo Molecular Technologies, Tokyo, Japan).\nCellular Binding and/or Internalization: 4T1 cells or mouse macrophage RAW 264.7 cells were incubated in confocal dishes for 24 h. Different formulations of nanoparticles (equivalent MOF dosage of 20 µg mL−1) were added incubated for 4 h. Cells were then washed with PBS, stained with Hoechst 33342, and observed by a confocal microscope. For quantitative analysis cells treated in the same manner were analyzed by flow cytometry.\nCellular GSH Assay: 4T1 cells were seeded into a six-well plate at a density of 1 × 105 cells and cultured for 24 h. After 5 h incubation with PBS, aM, aMM, or aMMTm (MOF concentration 20 µg mL−1), cells were washed with PBS and analyzed using the GSH assay kit according to the manufacturer’s protocol.\nTumor Cell Killing In Vitro Under Light Irradiance: 4T1 tumor cells were seeded in 96-well plates at a density of 5 × 103 cells per well. After 24 h incubation, cells were treated with PBS, aM, aMM, or aMMTm (MOF concentration 20 µg mL−1) or PBS for 5 h, then washed with PBS and into each well was added 100 µL fresh medium. Cells were then irradiated using a 660 nm light-emitting diode (LED) at 50 or 100 mW cm−2 for 15 min. After 12 h further incubation, the viability of cells was measured by CCK-8 assay. For live/dead cell staining and apoptosis analysis, 4T1 cells was treated and irradiated at 100 mW cm−2 as described above. At 2 h after irradiation, cells were either stained with Calcein-AM and PI for 10 min, washed with PBS, and observed by confocal microscopy, or stained with annexin V-FITC and PI and analyzed by flow cytometry.\nIn Vivo Pharmacokinetics: Normal BALB/c mice were administered with aM, aMM, or aMMTm (equivalent MOF dosage 10 mg kg−1; n = 3) intravenously. Blood samples were collected through tail incision at different time points and were analyzed for the MOF fluorescence (420 nm excitation, 660 nm emission).\nIn Vivo Tumor Targeting: Tumor bearing mice (tumor volume ≈ 300 mm3) were randomly divided into five groups (n = 3) and intravenously injected with aMMTm, aMMHm, aMMPm, aMML (equivalent MOF dosage 10 mg kg−1), or PBS, respectively. After 24 h, all the mice were imaged for MOF fluorescence. Subsequently, the mice were sacrificed and the major organs (including heart, liver, spleen, lung, kidney, and brain) and tumors were harvested for ex vivo imaging. To further verify the accumulation of these nanoparticles in tumors, tumors were embedded in Tissue-Tek optimal cutting temperature (OCT) compound and cryosectioned at 10 µm thickness for 4′,6-diamidino-2phenylindole (DAPI) staining and confocal observation.\nT1-Weighted MRI: For MRI analysis in vitro, aMMTm at different concentrations was incubated with or without 2 × 10−3 m GSH for 30 min before MR scanning. Mn content was quantified by inductively coupled plasma mass spectrometry (ICP-MS) (NexION 300X, Perkinelmer) to determine the T1 relaxation rate (r1). For in vivo imaging 4T1 tumor-bearing mice were administrated with aMMTm or aMML (MOF dosage 10 mg kg−1) via tail vein. MR images were acquired at different time points using a 7.0 T MR imaging machine (BioSpec 7.0 70/20, Bruker, Germany).\nIn Vivo Therapeutic Experiment: The 4T1 tumor model was established by subcutaneous injection of 5 × 106 4T1 cells at the right back of BALB/c female mice. All animal experiments were approved by the Institutional Animal Care and Use Committee of National Center for Nanoscience and Technology. When the tumor volume reached to about 70 mm3, the mice were intravenously administered with saline or different nanoparticle formulations once every 2 d for a total of three times, either accompanied or not by laser irradiation. The equivalent doses of MOF and apatinib in each injection were 10 and 5 mg kg−1 body weight, respectively. The mice were randomly divided into eight groups (n = 6) for the following treatments: 1) saline; 2) saline with light irradiation; 3) MMTm; 4) aMMTm; 5) MMTm with light; 6) aMML with light; 7) aMTm with light; and 8) aMMTm with light. For mice that received PDT, at 6 h after each injection the animal was exposed to a 660 nm LED with the irradiance of 100 mW cm−2 for 30 min. Body weight and tumor volume of the mice were monitored every 2 d during the whole experiment. Mice were euthanized at day 14 since the treatment started for further investigation. The tumor volume was calculated as following\n( ) ( ) ( )= × ×Tumor volume mm 0.5 width mm length mm3 2 2 (1) Hematological and Histological Analysis: Blood was collected from each mouse at day 14 and centrifuged at 2000 g for 15 min and the separated serum samples were tested for blood biochemical markers. The major organs (heart, liver, spleen, lung, and kidney) and the tumor were dissected and sectioned for H&E staining. To explore the therapeutic effect of the combination therapy, tumors were also stained for TUNEL, VEGFR2, and endothelial cell marker CD31 and proteins were extracted for Western blotting. All the hematological and histological analysis were carried out by Servicebio (Wuhan, China).\nStatistical Analysis: Data were examined statically using the SPSS17.0 statistical analysis software. All the error bars indicated mean ± s.d. Student t-test or one-way analysis of variance (ANOVA) followed by Tukey’s honestly significant difference (HSD) test was applied for comparison between two groups or among multiple groups, respectively, * indicated *p < 0.05, ** p < 0.01, and *** p < 0.001.\nSupporting Information Supporting Information is available from the Wiley Online Library or from the author.\nAdv. Mater. 2019, 1808200\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808200 (11 of 11)"
    }, {
      "heading" : "Acknowledgements",
      "text" : "H.M., J.W., and Y.Q. contributed equally to this work. This work was supported by the National Key R&D Program of China (2018YFA0208900), the National Natural Science Foundation of China (31700870, 31470969, 31700864, 31671023, and 51861145302), Beijing Municipal Science and Technology Commission Preclinical Program (Z161100000116026), the National Postdoctoral Program for Innovative Talents (BX20180083), the China Postdoctoral Science Foundation (2018M640100), Beijing Nova Program Interdisciplinary Cooperation Project (Z181100006218136), and Beijing Municipal Natural Science Foundation (7182126). H.M., J.W., Y.Q., Y.Z., Y.L., and G.N. conceived and designed the experiments. H.M., J.W., Y.Q., Y.Z., X.H., Y.X., J.X., Y.L., L.C., K.C., G.L., and N.Y. performed the experiments. H.M., Y.Q., Y.Z., Y.L., and G.N. collected and analyzed the data. Y.L., J.W., Y.L., and G.N. supervised the project. H.M., Y.L., J.W., Y.L., and G.N. wrote the paper. All authors discussed the results and commented on the paper."
    }, {
      "heading" : "Conflict of Interest",
      "text" : "The authors declare no conflict of interest."
    }, {
      "heading" : "Keywords",
      "text" : "angiogenesis inhibition, biomimetic nanoparticle, glutathione metabolism, MOF, photodynamic therapy\nReceived: December 20, 2018 Revised: January 27, 2019\nPublished online:\n[1] S. S. Lucky, K. C. Soo, Y. Zhang, Chem. Rev. 2015, 115, 1990. [2] H. Chen, Z. Gu, H. An, C. Chen, J. Chen, R. Cui, S. Chen, W. Chen,\nX. Chen, X. Chen, Z. Chen, B. Ding, Q. Dong, Q. Fan, T. Fu, D. Hou, Q. Jiang, H. Ke, X. Jiang, G. Liu, S. Li, T. Li, Z. Liu, G. Nie, M. Ovais, D. Pang, N. Qiu, Y. Shen, H. Tian, C. Wang, H. Wang, Z. Wang, H. Xu, J. Xu, X. Yang, S. Zhu, X. Zheng, X. Zhang, Y. Zhao, W. Tan, X. Zhang, Y. Zhao, Sci. China: Chem. 2018, 61, 1503. [3] W. Fan, P. Huang, X. Chen, Chem. Soc. Rev. 2016, 45, 6488. [4] Y. Li, T. Wen, R. Zhao, X. Liu, T. Ji, H. Wang, X. Shi, J. Shi, J. Wei,\nY. Zhao, X. Wu, G. Nie, ACS Nano 2014, 8, 11529. [5] S. Ye, J. Rao, S. Qiu, J. Zhao, H. He, Z. Yan, T. Yang, Y. Deng, H. Ke,\nH. Yang, Y. Zhao, Z. Guo, H. Chen, Adv. Mater. 2018, 30, 1801216. [6] H. He, S. Ji, Y. He, A. Zhu, Y. Zou, Y. Deng, H. Ke, H. Yang, Y. Zhao,\nZ. Guo, H. Chen, Adv. Mater. 2017, 29, 1606690. [7] M. Olivo, R. Bhuvaneswari, S. S. Lucky, N. Dendukuri,\nP. Soo-Ping Thong, Pharmaceuticals 2010, 3, 1507. [8] H. S. Jung, J. Han, H. Shi, S. Koo, H. Singh, H. J. Kim, J. L. Sessler,\nJ. Y. Lee, J. H. Kim, J. S. Kim, J. Am. Chem. Soc. 2017, 139, 7595. [9] M. Kaya, T. Wada, T. Akatsuka, S. Kawaguchi, S. Nagoya,\nM. Shindoh, F. Higashino, F. Mezawa, F. Okada, S. Ishii, Clin. Cancer Res. 2000, 6, 572. [10] M. I. Koukourakis, A. Giatromanolaki, J. Skarlatos, L. Corti, S. Blandamura, M. Piazza, K. C. Gatter, A. L. Harris, Cancer Res. 2001, 61, 1830. [11] A. Ferrario, K. von Tiehl, S. Wong, M. Luna, C. J. Gomer, Cancer Res. 2002, 62, 3956. [12] R. L. G. Lecaros, L. Huang, T. C. Lee, Y. C. Hsu, Mol. Ther. 2016, 24, 106.\n[13] B. Kosharskyy, N. Solban, S. K. Chang, I. Rizvi, Y. Chang, T. Hasan, Cancer Res. 2006, 66, 10953. [14] C. L. Peng, H. C. Lin, W. L. Chiang, Y. H. Shih, P. F. Chiang, T. Y. Luo, C. C. Cheng, M. J. Shieh, Photodiagn. Photodyn. Ther. 2018, 23, 111. [15] A. Ferrario, A. M. Fisher, N. Rucker, C. J. Gomer, Cancer Res. 2005, 65, 9473. [16] M. Seshadri, J. A. Spernyak, R. Mazurchuk, S. H. Camacho, A. R. Oseroff, R. T. Cheney, D. A. Bellnier, Clin. Cancer Res. 2005, 11, 4241. [17] H. Wang, Y. Wu, R. F. Zhao, G. J. Nie, Adv. Mater. 2013, 25, 1616. [18] C. Du, Y. Qi, Y. Zhang, Y. Wang, X. Zhao, H. Min, X. Han, J. Lang, H. Qin, Q. Shi, Z. Zhang, X. Tian, G. J. Anderson, Y. Zhao, G. Nie, Y. Yang, ACS Nano 2018, 12, 10785. [19] P. Rong, K. Yang, A. Srivastan, D. O. Kiesewetter, X. Yue, F. Wang, L. Nie, A. Bhirde, Z. Wang, Z. Liu, G. Niu, W. Wang, X. Chen, Theranostics 2014, 4, 229. [20] B. Tian, C. Wang, S. Zhang, L. Feng, Z. Liu, ACS Nano 2011, 5, 7000. [21] Q. Chen, L. Feng, J. Liu, W. Zhu, Z. Dong, Y. Wu, Z. Liu, Adv. Mater.\n2016, 28, 7129. [22] X.-Q. Wang, F. Gao, X.-Z. Zhang, Angew. Chem., Int. Ed. 2017, 56,\n9029. [23] K. Lu, T. Aung, N. Guo, R. Weichselbaum, W. Lin, Adv. Mater. 2018,\n30, 1707634. [24] J. Park, Q. Jiang, D. Feng, L. Mao, H.-C. Zhou, J. Am. Chem. Soc.\n2016, 138, 3518. [25] M. Lismont, L. Dreesen, S. Wuttke, Adv. Funct. Mater. 2017, 27,\n1606314. [26] T. Simon-Yarza, A. Mielcarek, P. Couvreur, C. Serre, Adv. Mater.\n2018, 30, 1707365. [27] T. Baati, L. Njim, F. Neffati, A. Kerkeni, M. Bouttemi, R. Gref,\nM. F. Najjar, A. Zakhama, P. Couvreur, C. Serre, P. Horcajada, Chem. Sci. 2013, 4, 1597. [28] S. Wuttke, A. Zimpel, T. Bein, S. Braig, K. Stoiber, A. Vollmar, D. Mueller, K. Haastert-Talini, J. Schaeske, M. Stiesch, G. Zahn, A. Mohmeyer, P. Behrens, O. Eickelberg, D. A. Boeluekbas, S. Meiners, Adv. Healthcare Mater. 2017, 6, 1600818. [29] C. M. J. Hu, R. H. Fang, J. Copp, B. T. Luk, L. Zhang, Nat. Nanotechnol. 2013, 8, 336. [30] H. Sun, J. Su, Q. Meng, Q. Yin, L. Chen, W. Gu, P. Zhang, Z. Zhang, H. Yu, S. Wang, Y. Li, Adv. Mater. 2016, 28, 9581. [31] R. H. Fang, C. M. J. Hu, B. T. Luk, W. Gao, J. A. Copp, Y. Tai, D. E. O’Connor, L. Zhang, Nano Lett. 2014, 14, 2181. [32] S. Y. Li, H. Cheng, W. X. Qiu, L. Zhang, S. S. Wan, J. Y. Zeng, X. Z. Zhang, Biomaterials 2017, 142, 149. [33] J. Y. Zhu, D. W. Zheng, M. K. Zhang, W. Y. Yu, W. X. Qiu, J. J. Hu, J. Feng, X. Z. Zhang, Nano Lett. 2016, 16, 5895. [34] Z. Chen, P. Zhao, Z. Luo, M. Zheng, H. Tian, P. Gong, G. Gao, H. Pan, L. Liu, A. Ma, H. Cui, Y. Ma, L. Cai, ACS Nano 2016, 10, 10049. [35] Q. Zhang, D. Dehaini, Y. Zhang, J. Zhou, X. Chen, L. Zhang, R. H. Fang, W. Gao, L. Zhang, Nat. Nanotechnol. 2018, 13, 1182. [36] Y. j. Mi, Y. J. Liang, H. B. Huang, H. Y. Zhao, C. P. Wu, F. Wang, L. Y. Tao, C. Z. Zhang, C. L. Dai, A. K. Tiwari, X. X. Ma, K. K. W. To, S. V. Ambudkar, Z. S. Chen, L. W. Fu, Cancer Res. 2010, 70, 7981. [37] L. S. Lin, J. Song, L. Song, K. Ke, Y. Liu, Z. Zhou, Z. Shen, J. Li, Z. Yang, W. Tang, G. Niu, H. H. Yang, X. Chen, Angew. Chem. 2018, 130, 4996. [38] L. Rao, L. L. Bu, B. Cai, J. H. Xu, A. Li, W. F. Zhang, Z. J. Sun, S. S. Guo, W. Liu, T. H Wang, X. Z. Zhao, Adv. Mater. 2016, 28, 3460. [39] E. Blanco, H. Shen, M. Ferrari, Nat. Biotechnol. 2015, 33, 941.\nAdv. Mater. 2019, 1808200"
    } ],
    "references" : [ {
      "title" : "Chem",
      "author" : [ "S.S. Lucky", "K.C. Soo", "Y. Zhang" ],
      "venue" : "Rev. 2015, 115",
      "citeRegEx" : "1",
      "shortCiteRegEx" : null,
      "year" : 1990
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "201808200 Photodynamic therapy (PDT) is an emerging anticancer therapeutic approach that utilizes photosensitizers under light irradiation to generate reactive oxygen species (ROS) cytotoxic against solid tumors.[1,2] Already approved for clinical treatment of various types of malignancies, PDT presents several very attractive advantages, especially its minimally invasive and selective manner enabled by localized irradiation, leading to considerably lower side effects compared with conventional treatments.",
      "startOffset" : 212,
      "endOffset" : 217
    } ],
    "year" : 2019,
    "abstractText" : "Dr. H. Min, Prof. J. Wang, Dr. Y. Qi, Dr. Y. Zhang, Dr. X. Han, Dr. Y. Xu, Dr. J. Xu, Dr. Y. Li, Dr. L. Chen, Dr. K. Cheng, Dr. G. Liu, Dr. N. Yang, Prof. Y. Li, Prof. G. Nie CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology Beijing 100190, China E-mail: zhangyl@nanoctr.cn; liyy@nanoctr.cn; niegj@nanoctr.cn Prof. J. Wang, Dr. Y. Zhang, Dr. X. Han, Dr. Y. Xu, Dr. J. Xu, Dr. L. Chen, Dr. N. Yang, Prof. Y. Li, Prof. G. Nie Center of Materials Science and Optoelectronics Engineering University of Chinese Academy of Sciences Beijing 100049, China Dr. Y. Qi School of Basic Medical Sciences Zhengzhou University Zhengzhou, Henan 450001, P. R. China The ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adma.201808200.",
    "creator" : "Adobe InDesign CS6 (Macintosh)"
  }
}